Eyepoint Pharmaceuticals’ (EYPT) “Underweight” Rating Reiterated at JPMorgan Chase & Co.

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “underweight” rating reaffirmed by equities researchers at JPMorgan Chase & Co. in a note issued to investors on Tuesday, Marketbeat reports.

A number of other analysts also recently weighed in on the stock. Mizuho reiterated a “neutral” rating and issued a $0.50 price target on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. HC Wainwright reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Royal Bank Of Canada reissued a “sector perform” rating and set a $5.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Weiss Ratings raised shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Finally, Wall Street Zen raised shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 27th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $21.85.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT traded up $0.01 during trading hours on Tuesday, hitting $0.45. The stock had a trading volume of 7,385,576 shares, compared to its average volume of 3,054,316. The company’s fifty day moving average is $4.77 and its two-hundred day moving average is $10.30. Eyepoint Pharmaceuticals has a 52 week low of $0.40 and a 52 week high of $19.11. The stock has a market capitalization of $38.97 million, a price-to-earnings ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The company had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Equities analysts predict that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System lifted its holdings in shares of Eyepoint Pharmaceuticals by 2,158.3% in the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock worth $1,355,000 after acquiring an additional 100,447 shares during the last quarter. Commodore Capital LP bought a new position in shares of Eyepoint Pharmaceuticals in the first quarter worth about $36,414,000. Walleye Capital LLC bought a new position in shares of Eyepoint Pharmaceuticals in the first quarter worth about $3,869,000. Swiss National Bank bought a new position in shares of Eyepoint Pharmaceuticals in the first quarter worth about $1,900,000. Finally, Stempoint Capital LP lifted its holdings in shares of Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after acquiring an additional 456,915 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Some analysts see potential recovery value at the current price. Mizuho maintained its neutral rating while assigning a $0.50 price target, and Jefferies moved to hold with a $1.00 target. These targets imply substantial upside from the current $0.44 level, although both firms remain cautious. TickerReport analyst coverage
• Positive Sentiment: Unusual options activity included the purchase of 7,885 call contracts, about 69% above typical daily volume, suggesting some traders are positioning for a potential rebound. However, options activity is not confirmation of a fundamental recovery.
• Neutral Sentiment: HC Wainwright and Mizuho reaffirmed neutral ratings. Their stance indicates limited conviction that the remaining pipeline currently supports a bullish investment case.
• Negative Sentiment: JPMorgan downgraded EyePoint from neutral to underweight, while Guggenheim cut its rating from buy to neutral. The downgrades reflect reduced confidence after the LUCIA setback.
• Negative Sentiment: EyePoint is cutting 53% of its workforce and halting wet AMD clinical trials early after disappointing LUCIA results. The company is redirecting resources toward DURAVYU’s diabetic macular edema program, but the restructuring underscores the loss of a major development catalyst. Benzinga workforce and clinical-trial report
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses after the trial disclosure. The investigation adds legal and reputational risk. Levi and Korsinsky investigation notice

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.